ProfileGDS5678 / 1423933_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 27% 29% 52% 29% 23% 26% 79% 80% 47% 22% 55% 26% 29% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6879229
GSM967853U87-EV human glioblastoma xenograft - Control 22.624127
GSM967854U87-EV human glioblastoma xenograft - Control 32.6666429
GSM967855U87-EV human glioblastoma xenograft - Control 43.2026952
GSM967856U87-EV human glioblastoma xenograft - Control 52.6119929
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5983323
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6491826
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5288379
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6765380
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0879747
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.506922
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3269255
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5974226
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6553129